display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
non squamous - mNSCLC - L1 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel IMpower-150 ...
atezolizumab plus carboplatin plus nab-paclitaxel IMpower-130 ...
atezolizumab plus carboplatin plus paclitaxel IMpower-150 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons